ROCO
3205
Market cap98mUSD
Oct 08, Last price
46.60TWD
1D
0.11%
1Q
-10.56%
Jan 2017
-62.87%
IPO
81.82%
Name
Sagittarius Life Science Corp
Chart & performance
P/E
—
P/S
9.10
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.56%
Rev. gr., 5y
-9.12%
Revenues
346m
-26.01%
Net income
-50m
L+2.13%
CFO
-36m
L-18.96%
Dividend
Aug 31, 20181.605 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sagittarius Life Science Corp, established in 1998 and headquartered in Taipei, Taiwan, focuses on the innovation, development, and sale of both traditional Chinese and modern Western pharmaceuticals, alongside nutritional supplements. Its market reach extends throughout Taiwan and the broader Asian region. Beyond its primary healthcare offerings, the company also provides a variety of organic food products, household essentials, and pet sustenance. A significant part of its activities includes pioneering advancements through biotechnology research and development initiatives.
Key people
Qingzong Yang
Chairman of the Board · since 2025
Chaowai Yang
General Manager · since 2026
Junheng Chen
Director · since 2025
Yunren Chen
Director · since 2025
Guofen Shi
Vice Chairman of the Board · since 2025
Cathy Wu
Deputy General Manager, Acting Head of Finance & Accounting, Acting Corporate Governance Officer, Director · since 2025
Rongchao Chen
Independent Director · since 2025
Shixun Lin
Independent Director · since 2025
Jianneng Zhong
Independent Director · since 2017
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||